Claim your 1.0hr CE/CME Credit Here
Name
*
First Name
Last Name
Email
*
example@example.com
What best describes your title?
*
MD/DO
RN/NP
PA
PharmD/RPh
Respiratory Therapist
Non-Clinician Research Coordinator
Other
If MD/DO
cardiologist (interventional)
cardiologist (heart failure)
cardiologist (lipid/vascular)
cardiologist (electrophysiology)
cardiologist (general)
endocrinologist
nephrologist
emergency medicine specialist
neurologist
stroke neurologist
critical care specialist
pulmonologist
primary care provider
industry
Other
If RN/NP
NPP
ICU
cath lab
ward
clinic
academic
industry
Other
If PharmD
hospital/health system-based
community
academic
industry
Other
If PharmD, DOB
-
Month
-
Day
Year
2 digit month, 2 digit day, 4 digit year
Date
If PharmD, NABP ID#
Where are you based?
EU/GB
Canada
USA
Latin America
Australia/NZ
Asia
How did you FIRST hear about our tweetorials?
found it on Twitter searching in subject area
found it on twitter searching for CE/CME
found it on Twitter by following individual influencer
found it on Twitter by following institutional influencer
from LinkedIn
How many years have you been in practice?
How many patients per month do you typically see with the disease addressed in this tweetorial?
1. Which of the following statements is FALSE regarding male vs female patients with hyperlipidemia?
*
A. Females are more likely to have statin intolerance
B. CLEAR-Outcomes showed that males had a disproportionate CV benefit from bempedoic acid compared to females
C. Prior to enrollment in CLEAR-Outcomes, females were less likely than males to have had hyperlipidemia diagnosed
D. Females in CLEAR-Outcomes were less likely to be on any baseline lipid-lowering therapy than males
2. Regarding patients with obesity (BMI > 30) enrolled in CLEAR-Outcomes, which is FALSE?
*
A. During the course of the study, patients on bempedoic acid and patients on placebo both tended to lose weight
B. Uric acid increases in patients with obesity who were treated with bempedoic acid were similar to the study overall
C. Compared to patients on placebo, obese patients treated with bempedoic acid did NOT show significant decreases in BOTH MACE-3 & MACE-4
D. Compared to patients on placebo, obese patients treated with bempedoic acid experienced a decrease in LDL-C levels of 23%
3. In BRIDGE TIMI-73a, patients with moderate hypertriglyceridemia and established or increased risk of ASCVD treated with olezarsen vs placebo:
*
A. Achieved significantly greater rates of TG < 150mg/dl at both doses tested
B. Showed higher rates of thrombocytopenia and bleeding
C. Were more likely to have dysglycemia on treatment
D. Had significantly greater rates of decreased eGFR and of proteinuria
4. Did you follow the entire tweetorial?
*
Yes
No
5. Did you find this to be an effective learning tool?
*
Yes
No
6. On a scale of 1 to 5, how applicable to your clinical practice was the material in this tweetorial?
*
Not At All Pertinent
1
2
3
4
Extremely Pertinent
5
1 is Not At All Pertinent, 5 is Extremely Pertinent
7. How will this program change your practice?
*
Not pertinent to my practice
Reinforces my practice
Makes me want additional education
Will change my practice
8. Will you recommend @cardiomet_CE and/or this website to your colleagues?
*
Yes
No
-
Month
-
Day
Year
2 digit month, 2 digit day, 4 digit year
Date
Course Title
Claim Certificate
Should be Empty: